EU CAR T 2025
STRASBOURG
We are excited to be at EU CAR T 2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.
Learn more about our presence at EU CAR T 2025 below
CARE-TOGETHER: The First Italian Patient Support Program for CAR T Patients
Increasing CAR T delivery capacity in Certified Healthcare Facilities: An impact assessment of shifting resources from ASCT to CAR T in second-line treatment of diffuse large B-cell lymphoma
Optimizing Care After CAR T-cell Therapy: Reduction of In-hospital Monitoring Duration Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Infusion
Manufacturing Commercial Axicabtagene Ciloleucel (Axi-Cel) in Italy for Patients with Relapsed/Refractory NHL: A 2-Year Retrospective Analysis
IS A CURE IN R/R LYMPHOMA ON THE HORIZON?
Insights from ASH 2024
Plenary room, Schweitzer Auditorium
Palais de la Musique et des Congrès,
Place de Bordeaux, 67000,
Strasbourg, France
Join Prof Roch Houot, Dr. Victoria Campbell and Dr. Abdulwahab Albabtain as they look at answering this important question: are we heading towards a potential cure in relapsed/refractory lymphomas with CAR T?
They will discuss the latest data presented at ASH 2024, including long-term follow-up data and real-world evidence that demonstrates the transformative impact of CAR T and how management strategies have evolved, leadingto better outcomes for patients.
Join us on Friday 7th February, 13:00-13:45 CET in the Schweitzer Auditorium.
Chair: Professor Roch Houot
University Hospital of Rennes,
Rennes, France
13:00 PM - 13:05 PM
Welcome and introduction
Chair: Professor Roch Houot
University Hospital of Rennes,
Rennes, France
13:05 PM - 13:15 PM
CAR T in practice: insights and implications from real-world data
Dr Victoria Campbell
Western General Hospital,
Edinburgh, UK
13:15 PM - 13:25 PM
Optimising patient outcomes in CAR T care
Dr Abdulwahab Albabtain
King Faisal Specialist Hospital and Research Centre,
Riyadh, Saudi Arabia
13:25 PM - 13:35 PM
Are we moving towards a cure inR/R lymphoma?
All, facilitated by Chair:
Professor Roch Houot
13:35 PM - 13:45 PM
Wrap-up and Q&A
Abbreviations:
ASH, American Society of Hematology; CAR T, chimeric antigen receptor T cell; CPD, Continuing Professional Development;Q&A, question and answer; R/R, relapsed/refractory. This event has been submitted for CPD accreditation.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.